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Abstract 
For a number of years we have been following the medical literature to find a relationship 
between chronic treatment with methotrexate and breast cancer occurrence, because we 
had had in our clinic a female patient who had had two consecutive cancers following 
methotrexate treatment for rheumatoid arthritis (RA). We were much surprised to find in 
some papers that breast cancer incidence is low in women with RA. Since then, we have 
found several papers explaining the low incidence of breast cancer among women being 
under NSAIDs, but those papers are not univocal. Methotrexate is a known antifolate agent 
and it has been demonstrated that dietary shortage of folate is a risk factor for breast cancer 
development. 
 
Introduction 
In the last two decades there has been a growing interest in studying the appearance 
of secondary malignancies in conjunction with rheumatoid arthritis (RA) [1, 2]. The 
majority of the described malignancies included hematological malignancies – 
especially lymphoma, lung cancer, melanoma and Kaposi’s sarcoma [1–5]. Breast 
cancer incidence is not considered to be increased in RA, except, possibly, in Japanese 
women [3].  
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Case Report 
Our interest in the subject of secondary tumors in patients being treated chronically with 
immunosuppressive therapy, especially with methotrexate, started with the presentation of a 78-
year-old woman in our Oncology Institute. This patient had been treated for RA with small doses of 
prednisolone, up to 10 mg daily, and methotrexate, up to 12.5 mg once a week, for a period of 20 
years. She was then diagnosed with stage II infiltrating ductal carcinoma of the breast (T2N0M0), 
containing high levels of estrogen and progesterone receptors. Her general condition at that time was 
considered good and her Karnovsky status was 90%. Postoperative adjuvant treatment was 
commenced with tamoxifen and the therapy with prednisolone and methotrexate was continued 
unchanged. For 2 years after her breast cancer diagnosis, this patient continued to be without any 
evidence of breast cancer recurrence and she was free of any RA activity as well. At that time, Kaposi’s 
sarcoma lesions of the right inner thigh skin and foot were identified and confirmed by biopsy. It was 
then decided to cease the immunosuppressive therapy and to give the patient the opportunity to 
recover from her Kaposi’s sarcoma. Due to termination of prednisolone and methotrexate and in 
order to change previous immunosuppressive treatment, tetracycline (minocycline) and gold salts 
(Ridaura) were begun. As a result, almost a month later, a spontaneous resolution of some of the 
Kaposi’s lesions was observed. Some of the lesions shrunk and some even disappeared. This response 
was observed for a period of 30 days but as soon as the lesions started to regrow, a weekly treatment 
with vinblastine was started. Soon after the initiation of chemotherapy, our patient on her own 
volition stopped tamoxifen that had been prescribed to her earlier. 
After a while, lung metastases, confirmed by histology to be of breast cancer origin, were 
identified. Consequently, she was recommended to initiate an additional hormonal agent, idoxifene. 
Unfortunately, she died of lung insufficiency due to breast cancer metastases to her lungs. She did not 
have any signs of Kaposi’s sarcoma at the time of her death. 
Notably, with the vinblastine treatment a complete response was obtained in Kaposi’s sarcoma, 
lasting for 1 year.  
Discussion 
We reported this case since we had to optimize several clinical judgments regarding 
a combined approach to a multiple simultaneous problem, using 1 drug applicable for 2 
malignancies, breast carcinoma and Kaposi’s sarcoma. Our experience illustrated that 
even in the period of well-established guidelines, when clinicians are facing a special 
situation, they may sometimes have to make an individual clinical decision that 
matches a specific patient. In general, Vinca rosea derivates, especially vincristine and 
vinorelbine, are the chemotherapy protocols recommended for recurrent Kaposi’s 
sarcoma. Vinblastine is usually not used. Our fear that our patient, affected by chronic 
methotrexate use, might develop neutropenic fever, led to the clinical decision of using 
vinblastine rather than the other derivates, since vinblastine is in use for breast cancer 
treatment. Lately, neither signs of neutropenic fever, nor of Kaposi’s sarcoma were 
confirmed.  
Our wish to discuss this issue is generated by the controversial data. On the one 
hand, methotrexate is a recognized antifolate agent and chronic lack of folates is an 
accepted factor in breast cancer pathogenesis [6]. Yet, on the other hand, anti-
inflammatory non-steroidal drugs may reduce the risk of carcinogenesis in general, and 
of breast cancer specifically, during the lifetime [1–4]. Methotrexate has been used for 
many years in RA and in recent years a supplement of folinic acid is recommended by 
rheumatologists. In April 2005, the British Journal of Cancer published the first study 
which explored the level of DNA damage and folate status in mononuclear cells in  
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breast cancer and benign breast disease patients, providing some evidence that 
reduced folate may be implicated in the development of breast cancer [7]. 
Based on retrospective studies published in different journals it is indicated clearly 
that RA patients have a lower incidence of breast cancer, probably due to the fact that 
they are being treated with NSAIDs [6], even though we discovered that this issue is not 
univocal. In January 2009, an additional paper entitled ‘Use of Aspirin, Other 
Nonsteroidal Anti-Inflammatory Drugs, and Acetaminophen and Risk of Breast Cancer 
among Premenopausal Women in the Nurses’ Health Study II’ by Eliassen et al. was 
published in Archives of Internal Medicine. This paper supported the contrary claim that 
‘chemopreventive use of aspirin or other NSAIDs for breast cancer among 
premenopausal women is not warranted’ [8]. 
Conclusion 
Further prospective investigation is needed to explain and prove the association 
between immune diseases, immunosuppressive treatment with methotrexate, breast 
cancer, and Kaposi’s sarcoma. However, despite the lack of knowledge at present, one 
should keep in mind the possible link among these conditions, before prescribing 
prolonged immunosuppressive treatment. 
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